uses JavaScript to provide the best possible experience for our content, but your browser has it disabled. Learn how to enable it here.


Posted October 6, 2006

FDA Warns Mangosteen Juice Maker of Drug Promotions

On September 20, 2006, the U.S. Food and Drug Administration (FDA) sent a Warning Letter to the makers of Xango, a mangosteen juice product. The letter advised that distributors of the product were using brochures making health claims restricted to the promotion of drugs.

Health claims listed in brochures included anti-inflammatory, anti-Parkinson, anti-Alzheimer, and anti-depression effects, as well as cancer prevention, weight loss, and many others.

The FDA requested that Xango LLC, International advise the FDA of the specific steps it will take to prevent distributors from promoting the product in this manner. to-date has not conducted a Product Review of mangosteen supplements. The Xango product has, however, been voluntarily tested for athletic banned substances. It passed this testing and is listed at

For more information about the FDA warning, see the link below.